Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is a rapidly growing telehealth company, with a successful digital platform and strong financial performance. Their focus on long-term retention and efficient marketing strategies have yielded impressive results, with continued investments in technology and global expansion positioning the company for continued success. Despite competition, Hims & Hers has a positive outlook due to its strong business model and proven ability to drive growth.

Bears say

Hims & Hers Health is facing intense competition from both established healthcare giants and venture-backed startups, which could increase marketing and operational expenses, pressure margins, and lead to customer attrition. The company's recent entry into the GLP-1 market also presents unique risks, including potential regulatory challenges and higher operational costs. Despite its expanding treatment portfolio, Hims & Hers must carefully navigate these challenges to achieve its long-term revenue and profitability targets.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.